MeSH D057135 - wet macular degeneration
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Bayer | Aflibercept | Eylea |  | 2012-11-21 |  |  |
| Midas Pharma | Ranibizumab | Ranivisio |  | 2022-08-25 |  |  |
| Novartis | Brolucizumab | Beovu |  | 2019-10-07 | $188 M | Q2/20-Q2/23 |
| Ranibizumab | Lucentis |  | 2007-01-22 | $1,722 M | Q2/21-Q2/24 | |
| PharmaSwiss | Pegaptanib | Macugen |  | 2006-01-31 |  |  |
| Roche | Faricimab | Vabysmo |  | 2022-09-15 | $2,221.9 M | Q4/22-Q3/23 |
| Samsung Bioepis | Ranibizumab | Byooviz |  | 2021-08-18 |  |  |
| Stada Arzneimittel | Ranibizumab | Ximluci |  | 2022-11-09 |  |  |
Clinical Trials
Historical Success Rate
Phase 1
0%0/0
Phase 2
64%7/11
Phase 3
75%15/20
Approved: 9Overall Success rate: 0%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use